These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31004450)

  • 1. S-ICD is effective in preventing sudden death in arrhythmogenic cardiomyopathy athletes during exercise.
    Catto V; Dessanai MA; Sommariva E; Tondo C; Dello Russo A
    Pacing Clin Electrophysiol; 2019 Sep; 42(9):1269-1272. PubMed ID: 31004450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
    Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
    Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current indications for an implantable cardioverter defibrillator (ICD)].
    Arenja N; Schaer B; Sticherling C; Kühne M
    Ther Umsch; 2014 Feb; 71(2):111-6. PubMed ID: 24463381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sudden death related cardiomyopathies - Arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and exercise-induced cardiomyopathy.
    Goff ZD; Calkins H
    Prog Cardiovasc Dis; 2019; 62(3):217-226. PubMed ID: 31004608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous implantable cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy: Results from an Italian multicenter registry.
    Migliore F; Viani S; Bongiorni MG; Zorzi A; Silvetti MS; Francia P; D'Onofrio A; De Franceschi P; Sala S; Donzelli S; Ricciardi G; Menardi E; Giammaria M; La Greca C; Bauce B; Rigato I; Iliceto S; Bertaglia E; Diemberger I; Corrado D
    Int J Cardiol; 2019 Apr; 280():74-79. PubMed ID: 30661851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Sports for Young Patients With Implantable Cardioverter-Defibrillators: Long-Term Results of the Multinational ICD Sports Registry.
    Saarel EV; Law I; Berul CI; Ackerman MJ; Kanter RJ; Sanatani S; Cohen MI; Berger S; Fischbach PS; Burton DA; Dziura J; Brandt C; Simone L; Li F; Olshansky B; Cannom DS; Lampert RJ
    Circ Arrhythm Electrophysiol; 2018 Nov; 11(11):e006305. PubMed ID: 30520349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
    Orgeron GM; James CA; Te Riele A; Tichnell C; Murray B; Bhonsale A; Kamel IR; Zimmerman SL; Judge DP; Crosson J; Tandri H; Calkins H
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The subcutaneous cardioverter-defibrillator: When less is more].
    Kuschyk J; Rudic B; Akin I; Borggrefe M; Röger S
    Herzschrittmacherther Elektrophysiol; 2015 Jun; 26(2):123-8. PubMed ID: 26058997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sudden cardiac death: New approaches for implantable cardioverter-defibrillators (ICDs).
    Cappato R; Ali H
    Int J Cardiol; 2017 Jun; 237():38-41. PubMed ID: 28377192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.
    Schinkel AF
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):562-8. PubMed ID: 23673907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts.
    Lambiase PD; Gold MR; Hood M; Boersma L; Theuns DAMJ; Burke MC; Weiss R; Russo AM; Kääb S; Knight BP
    Heart Rhythm; 2016 May; 13(5):1066-1074. PubMed ID: 26767422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Prevalence of Inappropriate Shocks in Patients With Inherited Arrhythmia Syndromes With the Subcutaneous Implantable Defibrillator Single Center Experience and Long-Term Follow-Up.
    Rudic B; Tülümen E; Berlin V; Röger S; Stach K; Liebe V; El-Battrawy I; Dösch C; Papavassiliu T; Akin I; Borggrefe M; Kuschyk J
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.
    Corrado D; Calkins H; Link MS; Leoni L; Favale S; Bevilacqua M; Basso C; Ward D; Boriani G; Ricci R; Piccini JP; Dalal D; Santini M; Buja G; Iliceto S; Estes NA; Wichter T; McKenna WJ; Thiene G; Marcus FI
    Circulation; 2010 Sep; 122(12):1144-52. PubMed ID: 20823389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous implantable cardioverter-defibrillator: Initial experience.
    Galvão P; Cavaco D; Adragão P; Costa F; Carmo P; Morgado F; Bernardo R; Nunes M; Abecasis M; Neves J; Mendes M
    Rev Port Cardiol; 2014 Sep; 33(9):511-7. PubMed ID: 25242675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.